{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:18:48Z","timestamp":1761862728461},"reference-count":175,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ejso.2007.07.202","type":"journal-article","created":{"date-parts":[[2007,12,20]],"date-time":"2007-12-20T20:52:14Z","timestamp":1198183934000},"page":"289-296","source":"Crossref","is-referenced-by-count":24,"title":["Carcinoid syndrome"],"prefix":"10.1016","volume":"34","author":[{"given":"J.","family":"Bendelow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Apps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Poston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2007.07.202_bib1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2007.07.202_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/lt.500010207","article-title":"Overview: the management of metastatic carcinoid tumors","volume":"1","author":"Ramage","year":"1995","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2133.2004.06273.x","article-title":"Cutaneous manifestations of the malignant carcinoid syndrome","volume":"152","author":"Bell","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejso.2007.07.202_bib6","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","article-title":"Carcinoid tumors and fibrosis: an association with no explanation","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterisation and echocardiography","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib10","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"Moller","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11886-006-0019-9","article-title":"Carcinoid heart disease","volume":"8","author":"Connolly","year":"2006","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejso.2007.07.202_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1527-5299.2003.02396.x","article-title":"Isolated tricuspid stenosis and heart failure: a focus on carcinoid heart disease","volume":"9","author":"Thatipelli","year":"2003","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ejso.2007.07.202_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/003655202320621481","article-title":"Carcinoid heart disease: an update","volume":"236","author":"Quaedvlieg","year":"2002","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.ejso.2007.07.202_bib14","first-page":"10","article-title":"Cardiovascular abnormalities in patients with a carcinoid syndrome","volume":"60","author":"Meijer","year":"2002","journal-title":"Neth J Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11936-000-0035-9","article-title":"Carcinoid heart disease","volume":"2","author":"Di Luzio","year":"2000","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4065\/77.2.139","article-title":"Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years","volume":"77","author":"Simula","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejso.2007.07.202_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/hc37t1.094898","article-title":"Surgical management of left-sided carcinoid heart disease","volume":"104","author":"Connolly","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.cir.0000032884.55215.87","article-title":"Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodelling","volume":"106","author":"Connolly","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejso.2007.07.202_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0002-9149(99)80586-4","article-title":"Predictors of outcome of tricuspid valve replacement in carcinoid heart disease","volume":"75","author":"Robiolio","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejso.2007.07.202_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0735-1097(94)00374-Y","article-title":"Outcomes of cardiac surgery for carcinoid disease","volume":"25","author":"Connolly","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejso.2007.07.202_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10350-004-0765-y","article-title":"Indications for endoscopic polypectomy for rectal carcinoids and clinical usefulness of endoscopic ultrasonography","volume":"48","author":"Kobayashi","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejso.2007.07.202_bib22","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","article-title":"Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas","volume":"96","author":"Anderson","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.0.1510015","article-title":"Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours","volume":"151","author":"Kaltsas","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejso.2007.07.202_bib24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1148\/radiol.2322030515","article-title":"Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging \u2013 perfusion differences in malignant and benign lesions","volume":"232","author":"Schaefer","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.ejso.2007.07.202_bib25","first-page":"58","article-title":"Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET\/CT and PET\/MRI","volume":"11","author":"Seemann","year":"2006","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ejso.2007.07.202_bib26","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin-receptor imaging in the localization of neuroendocrine tumors","volume":"323","author":"Lamberts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1749-6632.1994.tb17291.x","article-title":"Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejso.2007.07.202_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1530\/eje.0.1310577","article-title":"[111In-DTPA-d-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment","volume":"131","author":"Janson","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejso.2007.07.202_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00006231-200405000-00004","article-title":"Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours","volume":"25","author":"Savelli","year":"2004","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ejso.2007.07.202_bib30","first-page":"427","article-title":"Molecular biology of somatostatin receptors","volume":"16","author":"Reisine","year":"1995","journal-title":"Endocr Rev"},{"issue":"S1","key":"10.1016\/j.ejso.2007.07.202_bib31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.dld.2003.11.007","article-title":"Somatostatin receptors and regulation of cell proliferation","volume":"36","author":"Bousquet","year":"2004","journal-title":"Dig Liver Dis"},{"issue":"S2","key":"10.1016\/j.ejso.2007.07.202_bib32","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1023\/A:1012420207244","article-title":"Somatostatin receptor subtype expression in human tumors","volume":"12","author":"Hofland","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.50.1.52","article-title":"Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with specific antibodies","volume":"50","author":"Kulaksiz","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2007.07.202_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/bjs.4069","article-title":"111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours","volume":"90","author":"Hashemi","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s002590000289","article-title":"99mTc-EDDA\/HYNAC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives","volume":"27","author":"Decristoforo","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/108497804773391702","article-title":"99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA\/HYNIC-[Tyr3]octreotide: an interpatient comparison of two novel technetium-99m labelled tracers for somatostatin receptor scintigraphy","volume":"19","author":"Gabriel","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ejso.2007.07.202_bib37","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s002590100628","article-title":"Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide","volume":"28","author":"Forster","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2007.07.202_bib39","first-page":"851","article-title":"MIBG therapy","volume":"vol. 2","author":"Hoefnagel","year":"1994"},{"key":"10.1016\/j.ejso.2007.07.202_bib40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/ejso.2001.1132","article-title":"131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome","volume":"27","author":"Pathirana","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jc.86.2.895","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejso.2007.07.202_bib42","first-page":"68","article-title":"Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies","volume":"44","author":"Eriksson","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1196\/annals.1294.027","article-title":"PET in the diagnosis of neuroendocrine tumors","volume":"1014","author":"Sundin","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejso.2007.07.202_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1749-6632.2002.tb04422.x","article-title":"The role of PET in localization of neuroendocrine and adrenocortical tumors","volume":"970","author":"Eriksson","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejso.2007.07.202_bib45","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejso.2007.07.202_bib46","first-page":"213","article-title":"64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors","volume":"42","author":"Anderson","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","author":"Hoegerle","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.ejso.2007.07.202_bib48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","article-title":"Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study","volume":"7","author":"Koopmans","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2007.07.202_bib49","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1023\/A:1012484626808","article-title":"Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy","volume":"12","author":"Virgolini","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","article-title":"Evaluation of positron emission tomography imaging using [68Ga]-DOTA-d-Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors","volume":"5","author":"Kowalski","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.ejso.2007.07.202_bib51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjsurg.2003.04.007","article-title":"Management of neuroendocrine liver metastases","volume":"187","author":"Sutcliffe","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1055-3207(02)00076-5","article-title":"Hepatic surgery for metastases from neuroendocrine tumors","volume":"12","author":"Sarmiento","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ejso.2007.07.202_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/bja\/87.3.447","article-title":"Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours","volume":"87","author":"Kinney","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ejso.2007.07.202_bib55","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/msy.2001.110426","article-title":"Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years","volume":"129","author":"Nave","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib56","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","article-title":"Neuroendocrine hepatic metastases: does aggressive management improve survival?","volume":"241","author":"Touzios","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib57","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.surg.2003.07.025","article-title":"Aggressive surgery for metastatic liver neuroendocrine tumors","volume":"134","author":"Norton","year":"2003","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib58","first-page":"1340","article-title":"Primary and secondary liver endocrine tumors: clinical presentation, surgical approach and outcome","volume":"49","author":"el Rassi","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejso.2007.07.202_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib60","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.gassur.2004.04.003","article-title":"Survival and functional quality of life after resection for hepatic carcinoid metastases","volume":"8","author":"Knox","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib61","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s002680010236","article-title":"Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients","volume":"24","author":"Soreide","year":"2000","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib62","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/msy.2001.117377","article-title":"Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors","volume":"130","author":"Yao","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib63","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib64","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1067\/msy.2001.118388","article-title":"Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver","volume":"130","author":"Chung","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/000313480206800803","article-title":"Cytoreductive surgery in patients with advanced-stage carcinoid tumors","volume":"68","author":"Gulec","year":"2002","journal-title":"Am Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib66","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/1097-0142(19950801)76:3<501::AID-CNCR2820760322>3.0.CO;2-X","article-title":"Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors","volume":"76","author":"Cozzi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/jsre.2000.5988","article-title":"Radiofrequency ablation treatment of refractory carcinoid hepatic metastases","volume":"95","author":"Wessels","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejso.2007.07.202_bib68","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","article-title":"Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors","volume":"26","author":"Hellmann","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/crad.2002.1129","article-title":"MR-guided laser thermal ablation of primary and secondary liver tumours","volume":"58","author":"Dick","year":"2003","journal-title":"Clin Radiol"},{"key":"10.1016\/j.ejso.2007.07.202_bib70","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.181.4.1811005","article-title":"Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief\u00a0of neuroendocrine symptoms","volume":"181","author":"Henn","year":"2003","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.ejso.2007.07.202_bib71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1677\/erc.0.0100463","article-title":"Ablative therapies for liver metastases of digestive endocrine tumours","volume":"10","author":"O'Toole","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00261-004-0258-4","article-title":"Radiofrequency ablation of neuroendocrine liver metastases \u2013 the Middlesex experience","volume":"30","author":"Gillams","year":"2005","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.ejso.2007.07.202_bib73","unstructured":"Navarra G, Ayav A, Weber JC, et\u00a0al. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases."},{"key":"10.1016\/j.ejso.2007.07.202_bib74","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00270-004-4082-6","article-title":"Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques","volume":"28","author":"Atwell","year":"2005","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ejso.2007.07.202_bib75","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1245\/s10434-006-9226-2","article-title":"Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors","volume":"14","author":"Jensen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib76","first-page":"757","article-title":"Surgical management for metastatic liver tumors","volume":"53","author":"Hirai","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejso.2007.07.202_bib77","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archsurg.141.10.1000","article-title":"Metastatic neuroendocrine hepatic tumors: resection improves survival","volume":"141","author":"Musunuru","year":"2006","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7819-4-35","article-title":"Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy","volume":"4","author":"Veenendaal","year":"2006","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","article-title":"Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors","volume":"13","author":"Osborne","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/107327480601300109","article-title":"The role of cytoreductive surgery as an adjunct to the management of metastatic neuroendocrine carcinomas","volume":"13","author":"Hodul","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejso.2007.07.202_bib81","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.surg.2004.11.007","article-title":"Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas","volume":"137","author":"Elias","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2007.07.202_bib83","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1749-6632.1994.tb17301.x","article-title":"Liver transplantation for hepatic metastases of neuroendocrine tumors","volume":"733","author":"Bechstein","year":"1994","journal-title":"N Y Acad Sci"},{"key":"10.1016\/j.ejso.2007.07.202_bib84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000658-199704000-00002","article-title":"Liver transplantation for metastatic neuroendocrine tumors","volume":"225","author":"Lang","year":"1997","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000658-199704000-00003","article-title":"Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report","volume":"225","author":"Le Treut","year":"1997","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib86","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/S0041-1345(03)00584-0","article-title":"Role of liver transplantation in the management of metastatic neuroendocrine tumors","volume":"35","author":"Fernandez","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ejso.2007.07.202_bib87","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1196\/annals.1294.029","article-title":"Liver transplantation for treatment of metastatic neuroendocrine tumors","volume":"1014","author":"Ahlman","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejso.2007.07.202_bib88","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.gassur.2003.11.010","article-title":"Liver transplantation for neuroendocrine tumors","volume":"8","author":"Florman","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib89","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/lt.20755","article-title":"Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients","volume":"12","author":"Frilling","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejso.2007.07.202_bib90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/lt.20702","article-title":"Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival","volume":"12","author":"van Vilsteren","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejso.2007.07.202_bib91","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1245\/ASO.2003.04.533","article-title":"Long-term survival after resection for primary hepatic carcinoid tumor","volume":"10","author":"Knox","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib92","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.sla.0000109155.89514.42","article-title":"Hepatic resection and transplantation for primary carcinoid tumors of the liver","volume":"239","author":"Fenwick","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib93","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1091-255X(02)00044-6","article-title":"Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors","volume":"6","author":"Schell","year":"2002","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib94","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1477-7819-3-75","article-title":"Local treatment in unresectable hepatic metastases of carcinoid tumors: experiences with hepatic artery embolization and radiofrequency ablation","volume":"3","author":"Meij","year":"2005","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib96","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejso.2007.07.202_bib97","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00042737-200012020-00004","article-title":"Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours","volume":"12","author":"Dominguez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2007.07.202_bib98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00330-002-1558-0","article-title":"Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors","volume":"13","author":"Roche","year":"2003","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejso.2007.07.202_bib99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000074522","article-title":"Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors \u2013 a retrospective single-center analysis","volume":"68","author":"Kress","year":"2003","journal-title":"Digestion"},{"key":"10.1016\/j.ejso.2007.07.202_bib100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1179\/joc.2004.16.3.293","article-title":"Intra-arterial chemoembolization in liver metastases from neuroendocrine tumors: a phase II study","volume":"16","author":"Fiorentini","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.ejso.2007.07.202_bib101","first-page":"349S","article-title":"Long-term outcome in patients with liver metastases from neuroendocrine tumors treated with chemoembolization","volume":"23","author":"Dong","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"key":"10.1016\/j.ejso.2007.07.202_bib103","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastrointestinal system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib104","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","article-title":"Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide","volume":"21","author":"Filosso","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2036.2003.01420.x","article-title":"Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience","volume":"17","author":"Garland","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejso.2007.07.202_bib107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejso.2007.07.202_bib108","first-page":"235S","article-title":"Octreotide acetate (LAR) dose effect on plasma octreotide levels: impact on neuroendocrine tumor management","volume":"23","author":"Woltering","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib109","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/00365520410005225","article-title":"Treatment of ECL cell carcinoids with octreotide LAR","volume":"39","author":"Fykse","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib110","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1572-0241.1998.465_q.x","article-title":"Slow-release lanreotide treatment in endocrine gastrointestinal tumors","volume":"93","author":"Tomassetti","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib111","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib112","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib113","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib114","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib115","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib116","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1365-2265.2000.01126.x","article-title":"Complete histological regression of metastatic carcinoid tumour after treatment with octreotide","volume":"53","author":"Imtiaz","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejso.2007.07.202_bib117","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.10062","article-title":"Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature","volume":"79","author":"Leong","year":"2002","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib118","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3748\/wjg.v11.i13.2041","article-title":"Regression of liver metastases of occult carcinoid tumour with slow release lanreotide therapy","volume":"11","author":"Bondanelli","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2007.07.202_bib119","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib120","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1023\/A:1026592025862","article-title":"Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice","volume":"11","author":"Taal","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib121","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00006231-200008000-00009","article-title":"Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG","volume":"21","author":"Hoefnagel","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ejso.2007.07.202_bib122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytomas, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejso.2007.07.202_bib123","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters","volume":"89","author":"Kolby","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib124","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00268-004-7603-1","article-title":"131I-meta-iodobenzylguanidine in the management of midgut carcinoid tumors","volume":"28","author":"Sywak","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib125","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/cncr.20592","article-title":"Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients","volume":"101","author":"Safford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib126","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/bjs.5189","article-title":"Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues","volume":"92","author":"van Eijck","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib127","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","article-title":"Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver","volume":"81","author":"Slooter","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib128","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotide. State of the art perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00007611-200093080-00015","article-title":"High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor","volume":"93","author":"Meyers","year":"2000","journal-title":"South Med J"},{"key":"10.1016\/j.ejso.2007.07.202_bib130","first-page":"1","article-title":"Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib131","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib132","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib133","first-page":"206","article-title":"Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA, Tyr3]octreotide: toxicity and efficacy of 4-cycle and single-cycle regimens","volume":"23","author":"Valkema","year":"2004","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib134","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib135","first-page":"62S","article-title":"Overview of results of peptide receptor radionuclide therapy with 3 radiolabelled somatostatin analogs","volume":"46","author":"Kwekkeboom","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib136","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/BF03344149","article-title":"Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)","volume":"29","author":"Davi","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejso.2007.07.202_bib137","first-page":"96","article-title":"New clinical trials for the treatment of neuroendocrine tumors","volume":"44","author":"Bajetta","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib138","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2002.01589.x","article-title":"Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil","volume":"57","author":"Kaltsas","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"S2","key":"10.1016\/j.ejso.2007.07.202_bib139","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1023\/A:1012465801251","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"issue":"S1","key":"10.1016\/j.ejso.2007.07.202_bib140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000051859","article-title":"Chemotherapy in the treatment of neuroendocrine malignant tumors","volume":"62","author":"Rougier","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.ejso.2007.07.202_bib141","first-page":"4087","article-title":"Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment","volume":"21","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejso.2007.07.202_bib142","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2007.07.202_bib143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2407-4-23","article-title":"A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine","volume":"4","author":"Hopfner","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib144","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1677\/erc.1.00810","article-title":"Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours","volume":"11","author":"Zuetenhorst","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ctrv.2003.07.002","article-title":"Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours","volume":"29","author":"Pape","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2007.07.202_bib146","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/B:DRUG.0000006177.46798.1f","article-title":"Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group","volume":"22","author":"Stuart","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejso.2007.07.202_bib147","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lungcan.2003.11.016","article-title":"Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy","volume":"44","author":"Wirth","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib148","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubacin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib149","first-page":"361S","article-title":"Effective treatment of neuroendocrine tumors with temozolomide and capecitabine","volume":"23","author":"Fine","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib150","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","article-title":"A phase II study of high-dose paclitaxel with advanced neuroendocrine tumors","volume":"91","author":"Ansell","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/CNV-200029058","article-title":"A phase II study of docetaxel in patients with metastatic carcinoid tumors","volume":"22","author":"Kulke","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ejso.2007.07.202_bib152","first-page":"373S","article-title":"Paclitaxel, carboplatin and etoposid (TCE) in the treatment of advanced neuroendocrine tumours","volume":"23","author":"Kegel","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib153","first-page":"322S","article-title":"Paclitaxel\/carboplatin\/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: a Minnie Pearl Cancer Network phase II trial","volume":"23","author":"Miranda","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib154","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/sj.bjc.6601346","article-title":"A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)","volume":"89","author":"Hopfner","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2007.07.202_bib155","first-page":"310S","article-title":"A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors","volume":"23","author":"Kulke","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib156","first-page":"328S","article-title":"Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II Consortium (P2C) study","volume":"23","author":"Hobday","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib157","first-page":"198","article-title":"Rapid decrease in blood flow, blood volume and vascular permeability in carcinoid patients treated with bezacizumab","volume":"23","author":"Yao","year":"2004","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib158","first-page":"309S","article-title":"Improved progression free survival, and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab","volume":"23","author":"Yao","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib159","first-page":"329S","article-title":"Increased rate of hypertension among patients with advanced carcinoid treated with bevacizumab","volume":"23","author":"Mares","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib160","first-page":"343","article-title":"A phase II trial of imatinib in patients with advanced carcinoid tumor","volume":"23","author":"Carr","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.ejso.2007.07.202_bib161","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors","volume":"10","author":"Shah","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2007.07.202_bib162","first-page":"215S","article-title":"A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas","volume":"23","author":"Duran","year":"2005","journal-title":"Proc Am Soc Clin Oncol Annu Meet"},{"issue":"2","key":"10.1016\/j.ejso.2007.07.202_bib163","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/00207411.1994.11449284","article-title":"The EORTC modular approach to quality of life assessment in oncology","volume":"23","author":"Aaronson","year":"1994","journal-title":"Int J Ment Health"},{"key":"10.1016\/j.ejso.2007.07.202_bib164","series-title":"The international assessment of health-related quality of life: theory, translation, measurement and analysis","first-page":"3","article-title":"The international assessment of health-related quality of life: a theoretical perspective","author":"Shumaker","year":"1995"},{"key":"10.1016\/j.ejso.2007.07.202_bib165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2354.2003.00322.x","article-title":"Distress, quality of life and strategies to \u2018keep a good mood\u2019 in patients with carcinoid tumours: patient and staff perceptions","volume":"12","author":"Larsson","year":"2003","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ejso.2007.07.202_bib166","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/02841860152703445","article-title":"Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours","volume":"40","author":"Larsson","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib167","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1008360718646","article-title":"Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours","volume":"10","author":"Larsson","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib168","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/028418699432022","article-title":"Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract","volume":"38","author":"Larsson","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib169","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2796.1995.tb01175.x","article-title":"Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial","volume":"237","author":"Jacobsen","year":"1995","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejso.2007.07.202_bib170","unstructured":"Jones LE. Patient perceptions and experiences of fatigue with metastatic carcinoid disease. MSc thesis, University of Liverpool; 2005."},{"key":"10.1016\/j.ejso.2007.07.202_bib171","article-title":"Development of a disease-specific EORTC quality of life score questionnaire for patients with gastrointestinal tumours","author":"Davies","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.ejso.2007.07.202_bib172","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2007.07.202_bib173","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-642-83419-6_27","article-title":"A modular approach to quality of life assessment in cancer clinical trials","volume":"111","author":"Aaronson","year":"1998","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"10.1016\/j.ejso.2007.07.202_bib174","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00434800","article-title":"The European organisation for research and treatment of cancer approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on quality of life","volume":"2","author":"Sprangers","year":"1993","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.ejso.2007.07.202_bib175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1008890401133","article-title":"The European organisation for research and treatment of cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group","volume":"7","author":"Sprangers","year":"1998","journal-title":"Qual Life Res"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798307005185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798307005185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:46:46Z","timestamp":1708447606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798307005185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0748798307005185"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2007.07.202","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}